Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L ADAMS

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1995
SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shockL A Marshall, R H Hall, J D Winkler, et al.
The Veterinary Record|July 28, 2009
Suspected transmission of Mycobacterium bovis between alpacasD F Twomey, T R Crawshaw, A P Foster, et al.
The Journal of Biological Chemistry|June 23, 1998
Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocketR J Gum, M M McLaughlin, S Kumar, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymesJ L Adams, J C Boehm, S Kassis, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|October 29, 2000
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lungD C Underwood, R R Osborn, S Bochnowicz, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1995
Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthmaM C Chabot-Fletcher, D C Underwood, J J Breton, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 29, 2000
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistenceD C Underwood, R R Osborn, C J Kotzer, et al.
Arthritis and Rheumatism|January 22, 2000
Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritisA M Badger, D E Griswold, R Kapadia, et al.
HIV Medicine|February 26, 2013
Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot studyJ B Dumond, J L Adams, H M A Prince, et al.
Journal of Medicinal Chemistry|June 1, 2001
Potent and selective nonpeptide inhibitors of caspases 3 and 7D Lee, S A Long, J H Murray, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1995
SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shockL A Marshall, R H Hall, J D Winkler, et al.
The Veterinary Record|July 28, 2009
Suspected transmission of Mycobacterium bovis between alpacasD F Twomey, T R Crawshaw, A P Foster, et al.
The Journal of Biological Chemistry|June 23, 1998
Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocketR J Gum, M M McLaughlin, S Kumar, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymesJ L Adams, J C Boehm, S Kassis, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|October 29, 2000
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lungD C Underwood, R R Osborn, S Bochnowicz, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1995
Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthmaM C Chabot-Fletcher, D C Underwood, J J Breton, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 29, 2000
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistenceD C Underwood, R R Osborn, C J Kotzer, et al.
Arthritis and Rheumatism|January 22, 2000
Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritisA M Badger, D E Griswold, R Kapadia, et al.
HIV Medicine|February 26, 2013
Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot studyJ B Dumond, J L Adams, H M A Prince, et al.
Journal of Medicinal Chemistry|June 1, 2001
Potent and selective nonpeptide inhibitors of caspases 3 and 7D Lee, S A Long, J H Murray, et al.
Pageof 10